echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Cancer Cell Zhang Zemin's research group and collaborators reveal the mechanism of action of anti-PD-L1 immunotherapy combined with chemotherapy in triple-negative breast cancer

    Cancer Cell Zhang Zemin's research group and collaborators reveal the mechanism of action of anti-PD-L1 immunotherapy combined with chemotherapy in triple-negative breast cancer

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    October 14, 2021, Biological forefront of innovation Medical Center (BIOPIC) Peking University, College of Life Sciences, Beijing future genetic diagnosis sophisticated Innovation Center (ICG) Zhang Zemin Task Force joint Chinese Academy of Medical Sciences Cancer Hospital Liu Zhihua Task Force, horse fly and Xu Bing River Task Force in the international journal Cancer Cell on the online form to Article published a report entitled Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer research papers


     

    Breast cancer ranks first among female malignant tumors.


     

    The differences in the results of different clinical trials suggest that different chemotherapeutic drugs may lead to different tumor microenvironment characteristics, which in turn affects the therapeutic effect of immune checkpoint inhibitors


     

    The researchers collected 78 paired samples from 22 TNBC patients (11 received atilizumab combined with paclitaxel chemotherapy, 11 received paclitaxel single-agent chemotherapy) before and after treatment, and integrated single-cell transcriptome sequencing, T cell receptor sequence sequencing and chromatin access sequencing have constructed a high-resolution transcriptome and epigroup dynamic map of TNBC patients' tumor microenvironment and peripheral blood-derived immune cells


     

    Figure 1 Project research plan and main conclusions

    By comparing the differences in the composition of tumors and peripheral blood immune cells of different responders in the combination therapy group, the researchers found that the tumor microenvironment of the responding patients was enriched in two groups of T cells with high expression of CXCL13 (CD8-CXCL13 and CD4-CXCL13).


     

    In addition, the researchers found that the tumor microenvironment of the responding patients was enriched in two groups of pro-inflammatory macrophages with high expression of CXCL9 and CXCL10, andthere was a significant positive correlation between these two groups of pro-inflammatory macrophages and CXCL13 + T cells


     

      The tumor microenvironment is a complex ecosystem, in which innate immune and adaptive immune cells, stromal cells, cancer cells and their interactions constitute a fine regulatory network that together determine the occurrence and development of cancer


     

      In summary, the study revealed the molecular mechanism of TNBC patients' sensitivity and resistance to anti-PD-L1 immunotherapy, identified key immune components and their dynamic changes under immune checkpoint inhibitors and paclitaxel chemotherapy regimens, and clarified The reason why paclitaxel chemotherapy combined with atelizumab cannot effectively increase the therapeutic effect of TNBC patients


     

      This internationally leading novel work is the largest single-cell omics study on TNBC tumor-related immune cells so far, and provides a reliable foundation for in-depth understanding of the immune characteristics of TNBC patients and the mechanism of action of immunotherapy combined with chemotherapy.


     

      Link to the paper: https://

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.